276 results about "Increasing insulin" patented technology

A pancreatic controller (102), comprising: a glucose sensor (118), for sensing a level of glucose or insulin in a body serum; at least one electrode (110, 112), for electrifying an insulin producing cell or group of cells; a power source (104) for electrifying said electrode with a pulse that does not initiate an action potential in said cell and has an effect of increasing insulin secretion; and a controller (106) which receives the sensed level and controls said power source to electrify said electrode to have a desired effect on said level.

A method, system, and computer program product related to the detection of physical activity using changes in heart rate. The method, system, and computer program product evaluates short term glucose demand and long term insulin action due to physical activity. The method, system, and computer program product is further related to the improvement of open and closed loop control of diabetes by accounting for the metabolic changes due to physical activity. The method, system, and computer program product is directed to detecting in real time the short and long term effects of physical activity on insulin action via heart rate analysis, and recommending changes in insulin dosing to compensate for the effects of physical activity. With these recommendations, the open and closed loop control of diabetes can be improved and steps can be taken to prevent hypoglycemia that may result from increased insulin sensitivity due to physical activity.

Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.

The present invention is concerned with a method for improving blood glucose control or for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject in need of such control which comprises administering to the subject a composition comprising a therapeutically effective amount of one or more quinones of Formula I.

A pancreatic controller, comprising: a glucose sensor, for sensing a level of glucose or insulin in a body serum; at least one electrode, for electrifying an insulin producing cell or group of cells; a power source for electrifying said electrode with a pulse that does not initiate an action potential in said cell and has an effect of increasing insulin secretion; and a controller which receives the sensed level and controls said power source to electrify said electrode to have a desired effect on said level.

Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.

A natural composition formulated to modulate multiple pathophysiological processes in order to facilitate homeostatic glucose metabolism in a patient, and more particularly to increase insulin sensitivity in the same. The natural composition is a safe and effective formulation for the etiological prevention and treatment of diseases, complications, conditions, or disorders associated with chronic or long-term destabilization of glucose metabolism.

Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and / or indirectly stimulatory of angiogenesis and / or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of the adrenergic receptor α2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes.

The invention relates, in part, to of Glu-boroPro containing compounds and methods of use thereof in the prevention or management of conditions that are associated with impaired glucose tolerance such as diabetes. The invention also relates to compositions of Glu-boroPro containing compounds and methods of use thereof in the prevention or management of conditions such as metabolic syndrome, dyslipidemias, inflammation, cardiovascular disorders such as hypertension and atherosclerosis, and to reduce body weight or prevent weight gain. The compounds of the invention are also useful in lowering levels of triglycerides, free fatty acids, C-reactive protein (CRP), HbA1C, total glycosylated hemoglobin (TGHb), in increasing insulin sensitivity index and in stimulating insulin release.

A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β / δ of the cells.

A method, system, and computer program product related to the detection of physical activity using changes in heart rate. The method, system, and computer program product evaluates short term glucose demand and long term insulin action due to physical activity. The method, system, and computer program product is further related to the improvement of open and closed loop control of diabetes by accounting for the metabolic changes due to physical activity. The method, system, and computer program product is directed to detecting in real time the short and long term effects of physical activity on insulin action via heart rate analysis, and recommending changes in insulin dosing to compensate for the effects of physical activity. With these recommendations, the open and closed loop control of diabetes can be improved and steps can be taken to prevent hypoglycemia that may result from increased insulin sensitivity due to physical activity.

The present invention relates to weight control, control of body fat and food intake, and provides useful methods for treating, inter alia, obesity, diabetes and insulin insensitivity, and conditions, diseases, and disorders relating thereto. The invention also relates to methods of identifying useful compounds relating to weight loss, food intake, diabetes, and obesity, among other things, based on the discovery that inhibiting Kv1.3 activity mediates decreased food intake, weight loss, decreased body fat, increase glucose uptake, and increased insulin sensitivity, among other things.

The invention belongs to the field of biofermentation engineering. A pharmaceutical medium and a fungal strain which have blood sugar lowering efficacy are used as bidirectional fermentation raw materials, wherein the pharmaceutical medium is mainly composed of the following raw materials: cornel, gynostemma, momordica grosvenori, winged euony twigs, balsam pear and polyrhachis vicina; the fungalstrain is composed of the following strains: inonotus obliquus, cordyceps, phellinus igniarius, polystictus versicolor, and grifola frondosa; and bi-directional multi-fungi fermentation is carried out between multiple edible and pharmaceutical fungi and Chinese herbal medicines by a bidirectional fermentation process, thus organisms in two kingdoms or three kingdoms are organically combined to obtain an entirely new blood-sugar-lowering pharmaceutical mycoplasm product. The obtained product can generate 1+1>2 physiological function efficiency for hypoimmunity, has the actions of obviously lowering blood sugar but not increasing insulin concentration, has significant positive effects on helping treating and controlling diabetic complications, and can be used as an oral medicament for preventing and treating diabetes or a health-care product for adjusting blood sugar.

Methods for treating diabetes by increasing the insulin secretion by administration of a GLP-1 receptor agonist and / or a DPP-IV inhibitor in combination with a proton pump inhibitor and optionally a PPAR agonist are provided.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

The invention relates to a solid beverage suitable for patients with diabetes mellitus, which is prepared in the following steps: mixing dry medicine power extracted from semen cassiae, gingkgo, fingered citron, barbary wolfberry fruit, green tea and raw hawthorn and the pulverized mixing powder of rhizoma polygonati, Chinese yam, tuckahoe, kudzuvine root and semen coicis; and then screening to form power for producing and preparing the solid beverage of the patients with diabetes mellitus. The special meal solid beverage has the obvious effects of systemically adjusting glucose metabolism, improving carbohydrate tolerance, insulin sensitivity, insulin function and microcirculation, lightening an insulin load, reducing blood fat and blood viscosity and eliminating radicals and adiposis hepatica. The special meal solid beverage is suitable for patients with diabetes mellitus, obesity, adiposis hepatica, hyperlipemia and hypertension and middle-aged and old people to have.

A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK / ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of the adrenergic receptor α2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, for increasing insulin sensitivity in a subject, or to treat or prevent a skin condition. The compounds have general formulas (I) or (II) wherein R1 is -C(=O)-X-(C2-C18 straight chain or branched) alkyl or -C(=O)-X-(C2-C18 straight chain or branched) alkenyl; each R2 is independently selected from hydrogen, and a -C(O)-X-(C2-C18 straight chain or branched) alkyl or a -C(O)-X-(C2-C18 straight chain or branched) alkenyl; and X is a covalent bond or O.

Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.

This application discloses methods for treating, preventing and / or alleviating the symptoms of type II diabetes and diabetes-related disorders or complications. The invention provides a novel approach to treating and managing disorders and symptoms related to elevated plasma glucose concentrations and insulin resistance, characterized by few side effects and low toxicity. In particular, the invention provides 2-hydroxy-benzoic anilide compounds and derivatives, and compositions thereof, which can control blood-glucose and increase insulin sensitivity by reducing plasma glucose concentration and cellular energy efficiency.

The present invention provides methods and compositions for reducing visceral fat by administering to the subject a therapeutically effective amount of a compound that increases the bioactive serum levels of insulin-like growth factor-1 (IGF-1) in the subject, thereby ameliorating negative effects of visceral obesity. The invention is useful in the treatment, prevention, or amelioration of one or more symptoms of visceral obesity or IGF-1 deficiency related condition, including, for example, cardiovascular disease and the metabolic syndrome.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B orα2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

The invention relates to the use of specific protein and / or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and / or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

The use of probiotic bacteria in the manufacture of a composition for administration to a woman in at least the third trimester of pregnancy for prevention of gestational diabetes, normalising plasma glucose concentration and / or increasing insulin sensitivity.

The invention relates to a chitosan oligosaccharide composite powder with adjuvant hpyerglycemic function. The chitosan oligosaccharide composite powder comprises, by weight, 40 to 60 parts of oat beta-glucan, 5 to 20 parts of chitosan oligosaccharide, 5 to 20 parts of sealwort extract, 3 to 8 parts of mulberry leaf extract, 2 to 6 parts of balsam pear extract, 0.05 to 0.5 part of chromium-rich yeast and 10 to 20 parts of a filler. The invention has the following advantages: the chitosan oligosaccharide composite powder is a chitosan oligosaccharide compound prepared from chitosan oligosaccharide and oat beta-glucan, used as main effective components, and a plurality of traditional Chinese medicinal active components, used as adjuvant materials, through refining in virtue of ultrasonic emulsification and spray drying technologies; the chitosan oligosaccharide composite powder has the advantages of good dissolvability, good dispersibility and high absorption and availability; all the components of the chitosan oligosaccharide composite powder cooperate with each other to exert substantial effect on promotion of blood glucose metabolism and maintenance and adjustment of the functions of the pancreas islet; moreover, a variety of active components included in the chitosan oligosaccharide composite powder has obvious synergism in improving the sensitivity of insulin and stabilizing postprandial blood sugar.